Skip to Content

Join the 'Herpes Zoster Meningitis' group to help and get support from people like you.

Herpes Zoster Meningitis News

There's a New Shingles Vaccine, Shingrix, -- Is It for You?

Posted 26 Oct 2017 by Drugs.com

THURSDAY, Oct. 26, 2017 – On the heels of approval of a better vaccine for the painful condition shingles, adults over 50 should plan to roll up their sleeves – again. The new vaccine, Shingrix, will likely be recommended even for those already inoculated with an older vaccine. An advisory panel of the U.S. Centers for Disease Control and Prevention recommended Wednesday that all adults 50 and older receive the new two-shot vaccine, just days after the U.S. Food and Drug Administration announced its approval of Shingrix. Shingrix, manufactured by GlaxoSmithKline, is more than 90 percent effective in preventing shingles, a painful skin disease that afflicts about one of every three people in the United States during their lifetime. If the CDC adopts the panel's recommendation, Shingrix will supplant the only other shingles vaccine available, the single-dose Merck product Zostavax. "The ... Read more

Related support groups: Herpes Zoster, Zostavax, Varicella-Zoster, Herpes Zoster Otitis Externa, Herpes Zoster Iridocyclitis, Shingrix, Herpes Zoster Peripheral Neuropathy, Herpes Zoster Meningitis, Herpes Zoster Myelitis

Expert Panel Recommends New Shingles Vaccine, Shingrix, as First-Line Treatment

Posted 26 Oct 2017 by Drugs.com

A new shingles vaccine that provides far more protection than its predecessor received the full blessing of a U.S. government vaccine advisory panel on Wednesday. In a close 8-7 vote, the Advisory Committee on Immunization Practices recommended that Shingrix be chosen over Zostavax as the shingles vaccine of choice in adults aged 50 and older, the Washington Post reported. Previously, a shingles vaccine had only been recommended for those aged 60 and older. The panel went even further, and recommended that anyone who has been vaccinated with the Zostavax vaccine be re-vaccinated with the Shingrix vaccine – that group numbers about 20 million people, the Post reported. In total, more than 40 million people will be affected by the new recommendations, the newspaper said. Shingles is an extraordinarily painful rash caused by the chickenpox virus. It tends to strike older adults. The U.S. ... Read more

Related support groups: Herpes Zoster, Zostavax, Herpes Zoster Iridocyclitis, Shingrix, Herpes Zoster Peripheral Neuropathy, Herpes Zoster Meningitis, Herpes Zoster Myelitis

New Shingles Vaccine, Shingrix, Approved by FDA

Posted 25 Oct 2017 by Drugs.com

A new, more effective shingles vaccine has been approved by the U.S. Food and Drug Administration. The new vaccine from GlaxoSmithKline will be the second shingles vaccine available in the U.S. market. The other is from Merck and was introduced in 2006, the Associated Press reported. Shingles is a painful condition caused by the chickenpox virus. Anyone who's had chickenpox carries the virus that causes shingles. A study funded by Glaxo found that the company's Shingrix vaccine prevented shingles in about 90 percent of people. Merck's Zostavax vaccine is about 50 percent effective, the AP reported. Shingrix will cost $280 for the required two shots. Zostavax costs $223. Most insurance plans cover the vaccination. Both vaccines are for adults 50 and older, but the Centers for Disease Control and Prevention recommends vaccination for people 60 and older, partly because vaccination loses ... Read more

Related support groups: Herpes Zoster, Zostavax, Herpes Zoster Iridocyclitis, Shingrix, Herpes Zoster - Prophylaxis, Zoster Vaccine Live, Herpes Zoster Peripheral Neuropathy, Zoster Vaccine (recombinant), Herpes Zoster Meningitis, Herpes Zoster Myelitis

Shingles Linked to Raised Heart Risks for Seniors, Study Finds

Posted 15 Dec 2015 by Drugs.com

TUESDAY, Dec. 15, 2015 – Seniors who develop the painful rash known as shingles appear to face a short-term increase in their risk for having a stroke or heart attack, new research indicates. The finding was based on the tracking of heart health among more than 67,000 newly diagnosed shingles patients who were aged 65 and older. The analysis revealed that stroke risk more than doubled in the first week following a shingles diagnosis, with heart attack risk also climbing, though not by quite as much. The risk for both appeared to return to normal within six months. "The study highlights when patients with shingles may be most vulnerable," explained study author Caroline Minassian, a research fellow in the faculty of epidemiology and population health at the London School of Hygiene & Tropical Medicine in England. "If we know when these events are more likely to happen, this may ... Read more

Related support groups: Heart Disease, Herpes Zoster, Zostavax, Cardiovascular Conditions and Disorders, Ischemic Heart Disease, Herpes Zoster Peripheral Neuropathy, Herpes Zoster Meningitis

Ask a Question

Further Information

Related Condition Support Groups

Herpes Zoster